Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hCG for recovery after androgen abuse cessation
ACTRN12621001753842Phase 4Withdrawn
- Sponsor
- Sydney Local Health District
- Start
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in anabolic-androgenic steroid use disorder (AASUD) and Hypoandrogenism (TD) comparing hCG with Saline placebo (2 arms). Primary endpoint: Primary: composite recovery of serum LH and FSH. Planned start Jan 2022; status: withdrawn.
02
Drugs
human chorionic gonadotropin
03
Conditions
anabolic-androgenic steroid use disorder (AASUD)Hypoandrogenism (TD)
Beyond the preview
Go deeper on ACTRN12621001753842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001753842.